Pak's proposal to grant consular access to Jadhav to be evaluated as per ICJ guidelines

Agencies

August 1, 2019

New Delhi, Aug 1: India on Thursday said that the proposal sent by Pakistan to grant consular access to Indian national Kulbhushan Jadhav tomorrow is being evaluated as per the guidelines provided by the International Court of Justice (ICJ).

"We have received a proposal from Pakistan. We are evaluating the proposal in the light of ICJ judgement. We will maintain communication with Pakistan in this matter through diplomatic channels," Ministry of External Affairs spokesperson Raveesh Kumar said in the weekly briefing.

The reaction came shortly after Pakistan announced to grant consular access to Jadhav, who is on a death row in the country and is presently lodged in a jail there.

"The proposal sent by Pakistan is being evaluated by us as per the guidelines given by ICJ. Whatever response is to be sent will be given by us timely through diplomatic channels," the spokesperson added.

The development comes two weeks after the ICJ ruled in favour of India on the issue of granting consular access to the former naval officer.

The ICJ, in its ruling, asked Pakistan to ensure "effective review and reconsideration of his conviction and sentences".

In a major win for India, the world court had continued its stay on the execution of the Indian national, held in a Pakistani jail on allegations of spying and found that Pakistan breached the Vienna Convention by not giving him consular access.

Comments

Add new comment

Coastaldigest.com reserves the right to delete or block any comments.
Coastaldigset.com is not responsible for its readers’ comments.
Comments that are abusive, incendiary or irrelevant are strictly prohibited.
Please use a genuine email ID and provide your name to avoid reject.

AstraZeneca to withdraw Covid-19 vaccine globally as demand dips after admitting side effects

News Network

May 8,2024

AstraZeneca said on Tuesday it had initiated the worldwide withdrawal of its COVID-19 vaccine due to a "surplus of available updated vaccines" since the pandemic.

The company also said it would proceed to withdraw the vaccine Vaxzevria's marketing authorizations within Europe.

"As multiple, variant Covid-19 vaccines have since been developed there is a surplus of available updated vaccines," the company said, adding that this had led to a decline in demand for Vaxzevria, which is no longer being manufactured or supplied.

According to media reports, the Anglo-Swedish drugmaker has previously admitted in court documents that the vaccine causes side-effects such as blood clots and low blood platelet counts.

The firm's application to withdraw the vaccine was made on March 5 and came into effect on May 7, according to the Telegraph, which first reported the development.

London-listed AstraZeneca began moving into respiratory syncytial virus vaccines and obesity drugs through several deals last year after a slowdown in growth as COVID-19 medicine sales declined.

Comments